The proteoglycan form of macrophage colony-stimulating factor (PG-M-CSF), but not M-CSF with a molecular weight of 85 kD (85-kD M-CSF), bound to immobilized basic fibroblast growth factor (bFGF), and, conversely, bFGF bound to immobilized PG-M-CSF, but not to the 85-kD M-CSF. PG-M-CSF has an additional amino acid sequence at its carboxyl terminus (part of a precursor sequence that is removed in 85-kD M-CSF by proteolytic processing) and it has one or two chondroitin sulfate glycosaminoglycan chains at the carboxyl terminus. Enzymatic removal of the chondroitin sulfate chain from PG-M-CSF had no effect on the binding between PG-M-CSF and bFGF. Ligand blotting analysis with radioiodinated bFGF showed that bFGF specifically bound ACROPHAGE colony-stimulating factor (M-CSF), a growth factor for mononuclear phagocytic cells,' has been identified by our group as a glycoprotein with a molecu- In addition to having a longer carboxyl terminus than the 43-kD subunit, the PG-M-CSF-specific subunit contains a chondroitin sulfate chain on the carboxyl terminal portion; this modification might concur with the 0-linked oligosaccharide modificaresidues-Ser-Gly-X-Gly/Ala) is present in the carboxyl terminus at Ser-277.3 Our recent experiments in examining M-CSF molecules by expression of mutagenized M-CSF cDNA in mammalian cells have shown that the replacement of the serine residue at 277 by an alanine residue resulted in the complete loss of the chondroitin sulfate modification with PG-M-CSF (F. Kimura, S. Suzu, K. Motoyoshi: manuscript in preparation); thus, a single chondroitin sulfate chain is attached at Ser-277. It has also been shown that the combination of the PG-M-CSF-specific subunit with the identical subunit or the 43-kD subunit lacking the carboxyl terminal structures yielded homodimeric or heterodimeric PG-M-CSF, respectively." 
molecule has been identified, by us and other^,^.^ as a species that carries a chondroitin sulfate glycosaminoglycan (GAG) chain, ie, it is a chondroitin sulfate proteoglycan and has been designated "proteoglycan form of M-CSF" (PG-M-CSF)."
Human M-CSF is produced as a 522-amino acid polypeptide preceded by a 32-amino acid signal ~e p t i d e .~
The precursor polypeptides are rapidly dimerized via disulfide bonds, cotranslationally glycosylated with N-linked oligosaccharides, and posttranslationally modified by the addition of 0-linked oligosaccharide^?^ Proteolytic cleavage at the residue around 223 produces an M-CSF subunit of 43 k D . 4 . 5 The 85-kD M-CSF is a homodimer of the 43-kD s u b~n i t .~-~ In contrast, proteolytic cleavage occurring at the residue around 400, but not at that around 223, produces a PG-M-CSFspecific subunit with an MW of 150 to 200 In addition to having a longer carboxyl terminus than the 43-kD subunit, the PG-M-CSF-specific subunit contains a chondroitin sulfate chain on the carboxyl terminal portion; this modification might concur with the 0-linked oligosaccharide modificaresidues-Ser-Gly-X-Gly/Ala) is present in the carboxyl terminus at Ser-277. 3 Our recent experiments in examining M-CSF molecules by expression of mutagenized M-CSF cDNA in mammalian cells have shown that the replacement of the serine residue at 277 by an alanine residue resulted in the complete loss of the chondroitin sulfate modification with PG-M-CSF (F. Kimura, S. Suzu, K. Motoyoshi: manuscript in preparation); thus, a single chondroitin sulfate chain is attached at Ser-277. It has also been shown that the combination of the PG-M-CSF-specific subunit with the identical subunit or the 43-kD subunit lacking the carboxyl terminal structures yielded homodimeric or heterodimeric PG-M-CSF, respectively." A great number of studies have shown that many of the proteoglycans function as modulators of growth factors." Growth factors that bind to heparan sulfate or heparin include granulocyte-macrophage CSF (GM-CSF), interle~kin-3,'~*'~ and fibroblast growth factors (FGF).15 The physiologic significance of these interactions appears to be that they create a reservoir of growth factors for cells to use." The growth factor-proteoglycan interactions described above are mediated by the GAG components of the proteoglycans. At least one growth factor, transforming growth factor-@ (TGF-P), binds to the core protein of a chondroitin/dermatan sulfate proteoglycan, decorin. 16 Decorin not only binds TGF-P, but also neutralizes the activity of the growth factor.I6
PG-M-CSF is a growth factor that acts on monocytes/ macrophages, but is, at the same time, a proteoglycan, as noted above. Therefore, we have investigated whether there are growth factors to which PG-M-CSF could bind. In a series of screenings, we found that PG-M-CSF bound to basic FGF (bFGF). In this report, we show the characteristics of the interaction between PG-M-CSF and bFGF and the effect of this interaction on bFGF activity. medium conditioned by CHO-3ACSF-69 cells.' PG-M-CSF was also purified from the conditioned medium, using an anti-M-CSF antibody-bound affinity column subsequent to a diethyl aminoethylSephacel column (Pharmacia, Uppsala, Sweden), as described previously'o (step-l preparation). PG-M-CSF was the major material in the step-l preparation that could be detected in silver-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. The experiments shown in Figs 1 through 4 were performed with the step-l preparation. Experiments in which the effects of PG-M-CSF on bFGF activity (Fig 5 ) were evaluated were performed with a PG-M-CSF preparation that was further purified. To obtain this (step-2 preparation), the step-l PG-M-CSF preparation was subjected to high-performance liquid chromatography (HPLC) on a TSK Phenyl-5-PW column (TOSOH, Tokyo, Japan) and to subsequent HPLC on a TSK Gel-G3000SWXL column (TOSOH). The two HPLC steps allowed the removal of minor contaminating proteins in the step-l preparation. After the final HPLC step, PG-M-CSF was purified to apparent homogeneity, because the PG-M-CSF eluted as a single peak with the M-CSF concentration profile detected by enzyme immunoassay corresponded exactly with the protein absorption profile, and PG-M-CSF was the only material in the step-2 preparation detectable by SDS-PAGE (S. Suzu, Y. Mishima, K. Motoyoshi: manuscript in preparation).
Preparation of PG-M-CSF-derived polypeptide.
The clone p3ACSFR1, consisting of a 1.8-kb insert that included the complete coding sequence of a human 4-kb M-CSF cDNA, was kindly provided by Genetics Institute, Inc (Cambridge, MA). 3 The sequence corresponding to amino acids 213 through 455 of the M-CSF protein was cloned in BarnHI sites of the pQE vector (QIA express-system; QIAGEN Inc, Catsworth, CA), upstream of the 6 X His-tag (tag for affinity purification consisting of six adjacent histidine residues). Escherichia coli strain M 15, harboring the construct was grown in 2 X YT medium, and expression was induced by adding isopropylthio-P-D-galactoside. to a concentration of 2 mmol/L. Cells were collected by centrifugation. Cell lysis and purification of the recombinant protein on an Ni-NTA column were performed with QIA express-system according to the manufacturer's instructions. The recombinant polypeptide was insoluble under nondenaturing conditions, so we added urea, at a final concentration of 8 mol/L, to the stock solution.
Reagenrs. Antibody against the 85-kD M-CSF was prepared by immunizing rabbits with the purified material, as described previously." Recombinant human bFGF was purchased from Genzyme Corp (Boston, MA). Radioiodinated human bFGF ("'I-bFGF) was purchased from Du Pont-New England Nuclear (Wilmington, DE), The interaction of PG-M-CSF and bFGF was studied by using a somewhat modified enzyme-linked immunosorbent assay (ELISA) procedure that has been reported previously."' bFGF diluted with cold phosphate-buffered saline (PBS) at a concentration of 2 pg/mL was added to the wells of a flat-bottomed 96-well microtiter plate (Costar 3950; Costar, Cambridge, MA), and the plate was allowed to stand overnight at 4°C. It was then washed with PBS and each well was incubated with PBS containing 3% bovine serum albumin (BSA) overnight at 4°C to saturate the remaining sites for protein binding. The plate was washed with PBS, after which various M-CSF samples diluted in PBS containing 1.5% BSA were added to each well. The assay was performed in duplicate. In selected experiments, PG-M-CSF was treated with chondroitinase AC (10 mUlmL, EC 4.2.2.5; Seikagaku Kogyo CO), before addition to the wells.' After a 2-hour incubation at 37°C. the plate was washed and anti-M-CSF rabbit IgG solution was added to each well. After a further 2-hour incubation at 3 7 T , the plate was again washed, and horseradish peroxidaseconjugated goat IgG against rabbit IgG (Bio-Rad, Richmond, CA) was added. After a final 2-hour incubation at 37°C. the plate was washed extensively, and the bound peroxidase activity was measured with o-phenylenediamine, as described previously. For .l pgimL heparin (HEPO.1). or 1 pglmL heparin (HEPI) for 3 hours (A) or 20 hours (B) . The amount of incorporated BrdU in each well was estimated, and percent DNA synthesis was calculated as described in Materials and Methods.
of 85-kD M-CSF or PG-M-CSF was coupled to 1 mL of Formyl cellulofine (Seikagaku Kogyo CO), according to the manufacturer's instructions. To determine the binding of bFGF to the M-CSF-Formy1 cellulofine, 100 pL of each resin was incubated with I pg of bFGF dissolved in 100 pL PBS containing 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-I-propanesulfonate (CHAPS) overnight at room temperature, with continuous mixing. After incubation, the resin was washed four times with PBSl0. I % CHAPS (binding buffer) and three times with the binding buffer containing 3 molL NaCl. The eluents from M-CSF-Formyl cellulofine affinity chromatography were analyzed by electrophoresis under reducing conditions on SDS-polyacrylamide 4% to 12% gradient gel and by subsequent silver staining of the gel.
'251-bFGF ligand blotting. Proteins resolved by SDS-PAGE under either reducing or nonreducing conditions were visualized by silver staining." In a ligand-blot analysis, the proteins resolved on SDS-PAGE gel were electroblotted onto a nylon membrane (Immobillon PVDF Millipore, Bedford, MA) as described previouslyx~"; the electroblotted proteins were allowed to react with '"I-bFGF (0.16 pCi/mL) for 4 hours at room temperature. The nylon membranes were extensively washed with PBS containing 0.05% Tween 20, and the reacted proteins were visualized by an autoradiography.
Mitogenic assay. Mouse Balblc 3T3 cells, obtained from RIKEN Cell Bank (Tsukuba, Japan), were maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated calf serum (GIBCO). Cells ( I X lo4) in 0.1 mL DMEM supplemented with 5% calf serum were plated into the wells of 96-well tissue culture plates (Costar 3596). Four days later, the medium was aspirated and replaced with DMEM supplemented with ITS+ (insulin [6.25 ~g l m L ] , transferrin [6.25 pgl mL], BSA [l .25 mg/mL], and linoleic acid t5.35 pg/mL]; Collaborative Research, Bedford, MA). Simultaneously, the cells were stimulated with bFGF, in the presence or absence of heparin or PG"-CSF, for 20 hours at 37°C. The samples were prepared in a solution of 5 mg of BSA per milliliter of DMEM (BSADMEM) and were serially diluted with BSA/DMEM. Control solutions of either BSAl DMEM or calf serum were also included in each assay. All measurements were performed in duplicate. Subsequently, the cells were labeled with 10 pmolL 5-bromo-2'-deoxy-uridine (BrdU) and were incubated for an additional 4 hours at 37°C. The level of DNA synthesis was quantitated by determining BrdU incorporation, using the BrdU Labeling and Detection Kit I11 (Boehringer Mannheim Biochemica, Mannheim, Germany). In this system, the level of BrdU incorporated into cellular DNA can be determined by measuring the absorbance of each well at 405 nm. The percent DNA synthesis was calculated by the following formula: % DNA synthesis = 100 X [absorbance (well with sample) -absorbance (well with medium alone)]/[absorbance (well with 5% calf serum) -absorbance (well with medium alone)]. In selected experiments, Balb/c 3T3 cells were incubated with bFGF in the presence or absence of heparin or PG-M-CSF for only 3 hours, the cell culture medium was removed, and the monolayer was washed three times with DMEM/ITS+. The cell growth was then allowed to proceed in DMEM/ITS' without bFGF, heparin, or PG-M-CSF for a further 17 hours, and the plate was processed as above.
RESULTS

PG-M-CSF binds to immobilized bFGF.
We investigated whether PG-M-CSF bound to growth factors. In a series of screenings, we found that PG-M-CSF bound to immobilized bFGF (Fig 1A) . We did not detect any binding of PG-M-CSF to acidic FGF, TGF-P, platelet-derived growth factor, GM-CSF, tumor necrosis factor a, interferon y , interleukin-l, or stem cell factor (data not shown). Pretreatment of PG-M-CSF with chondroitinase AC did not affect the apparent level of PG-M-CSF binding to bFGF.
The 85-kD M-CSF showed no detectable affinity for bFGF, even when this M-CSF was included in the assay at a high concentration (100 ng/mL). Because bFGF has an affinity for GAG such as heparan sulfate or heparin,'' we examined the inhibitory activity of various GAG on the binding of PG-M-CSF to immobilized bFGF. As shown in Fig IB, heparan sulfate effectively inhibited the binding of PG-M-CSF to immobilized bFGF. Chondroitin sulfate B also inhibited the binding, but its inhibition was less effective than that of heparan sulfate. Chondroitin sulfate A and C were without effect. Taken together, these results show that the carboxyl terminal structures of PG-M-CSF, other than its chondroitin sulfate GAG, contain the primary binding site for bFGF, and that PG-M-CSF and heparan sulfate bind to adjacent regions of bFGF.
bFGF binds to immobilized PG-M-CSF and its carboxyl terminal polypeptide. We next examined the interaction between PG-M-CSF and bFGF in the reverse situation; ie, we examined the binding capacity of bFGF to wells coated with PG-M-CSF. The recombinant polypeptide correspondFor personal use only. on August 30, 2017 . by guest www.bloodjournal.org From ing to the carboxyl terminus of PG-M-CSF was also included in the assay to identify the structural components of PG-M-CSF responsible for bFGF binding. The polypeptide preparation was devoid of any contaminating proteins, as described below. As expected, bFGF effectively bound to the immobilized PG-M-CSF and chondroitinase AC-digested PG-M-CSF, but not to the immobilized 85-kD M-CSF (Fig 2A) . It should be noted that bFGF bound to the wells coated with the carboxyl terminal polypeptide (Fig 2A) and that the soluble PG-M-CSF, but not the 85-kD M-CSF, inhibited the binding (Fig 2B) , indicating that peptides in the carboxyl terminus of PG-M-CSF contribute greatly to its capture of bFGF. The result shown in Fig 2C, ie, the inhibitory activity of heparan sulfate on bFGF binding to the immobilized carboxyl terminal polypeptide, confirmed that the binding sites for PG-M-CSF and heparan sulfate were located close together on bFGF.
The nature of bFGF binding to PG-M-CSF was analyzed by affinity chromatography on PG-M-CSF-Formyl cellulofine. The results (Fig 3A) showed that most of the applied bFGF was bound to PG-M-CSF-Formyl cellulofine and could be eluted from the resin with 3 m o a NaCl. In our preliminary experiments, in which an ELISA for bFGF was set up and aliquots of each eluent were assayed for the content of bFGF, approximately 90% of the applied bFGF was found in the fractions of 3 m o m NaC1-elution (data not shown). Further, when the resin was further washed with PBS containing 8 m o a urea, no detectable bFGF signal on SDS-PAGE gel was observed with the fractions (data not shown). As expected, bFGF was not bound to 85-kD M-CSF-Formyl cellulofine and most of the applied bFGF was shown in the flow-through and the first PBS wash fractions (Fig 3B) .
I2'I-bFGF ligand blotting. We next performed a ligand blotting with "'I-bFGF to examine the specificity of bFGF binding to PG-M-CSF. PG-M-CSF migrated as a broad band when analyzed by SDS-PAGE under nonreducing conditions (Fig 4A, lane 2) . Treatment of PG-M-CSF with chondroitinase AC resulted in the appearance of two bands, at 150 and 200 kD (Fig 4A, lane 3) . The former represents the heterodimeric form of PG-M-CSF and the latter the homodimeric form, as described previously." In the ligand-blot analysis with "'I-bFGF, it was clearly shown that the band of PG-M-CSF, but not that of the 85-kD M-CSF, reacted with 1251-bFGF (Fig 4B, lanes l and 2) . The two bands appeared by chondroitinase AC-digestion, ie, the heterodimeric and homodimeric forms of PG-M-CSF also reacted with "'IbFGF, with the same apparent potency (Fig 4B, lane 3) . We next examined the reactivity of the carboxyl terminal polypeptide with "'1-bFGF. The recombinant proteins were purified on an Ni-NTA column, as described in Materials and Methods, and SDS-PAGE analysis of the preparation under reducing conditions gave a single sharp band at 28 kD (Fig 4A, lane 4) . In the ligand-blot analysis, "'I-bFGF was shown to bind to the carboxyl terminal polypeptide (Fig 4B, lane 4) . Excess unlabeled bFGF almost completely blocked the binding of "%bFGF to the polypeptide (Fig 4B,  lane 5) , indicating the specificity of this interaction for bFGF.
PG-M-CSF inhibits the mitogenic activity of bFGF. It is well known that heparinlike molecules present in the extracellular matrix (ECM) or on the cell surface bind bFGF and serve as a reservoir of the growth factor.15 More recent studies have shown that the binding of bFGF to its receptor requires prior binding of the growth factor to heparinlike molecules, namely, the binding of bFGF to heparinlike molecules is required for the biologic activity of the growth factor.19,20 Thus, the finding that the binding sites for PG-M-CSF and heparan sulfate are located close together on bFGF raises the possibility that PG-M-CSF could affect bFGF activity. In this study, we showed the inhibitory effect of PG-M-CSF on bFGF-induced DNA synthesis in Balb/c 3T3 cells by two assay systems. In one system, Balb/c 3T3 cells were incubated with bFGF in the presence or absence of PG-M-CSF or heparin for only 3 hours and without any additives for a further 17 hours. As shown in Fig 5A, the mitogenic response to bFGF was inhibited by PG-M-CSF and heparin in a dose-dependent fashion, but was not inhibited by 85-kD M-CSF. In another assay, cells were exposed to bFGF with or without PG-M-CSF or heparin continuously throughout the culture period. Figure 5B shows that PG-M-CSF also reduced the level of DNA synthesis induced by bFGF in this assay system, whereas heparin was less effective.
DISCUSSION
In this study, we have clearly shown that the carboxyl terminal peptides of PG-M-CSF specifically bind bFGF. The carboxyl terminal portion was also modified by both chondroitin sulfate GAG and 0-linked oligosaccharides,8 but such sugar moieties play no essential role in PG-M-CSF binding to bFGF. The finding that, in the ligand blot analysis, the monomeric carboxyl terminal polypeptide reacted with "' IbFGF (Fig 4) indicates that the dimeric structure of PG-M-CSF is unnecessary for the molecule to bind bFGF. The functional domains in the primary structure of the PG-M-CSF-carboxyl terminus responsible for the capture of bFGF have not yet been identified. In preliminary experiments, we studied the expression of a deletion mutant of M-CSF cDNA and found that the truncated PG-M-CSF, consisting of the amino terminal 301 residues, still had the binding capacity for immobilized bFGF ( S S , F.K., K.M., unpublished observations, March 1994). Because the 85-kD M-CSF, which shows no apparent affinity for bFGF, is thought to consist of the amino terminal 223 residues," it is possible that the binding domain for bFGF might reside in the amino acid sequence corresponding to residues 224 through 301. The binding sites for PG-M-CSF in bFGF have also not been defined. However, we confirmed that PG-M-CSF competes with heparan sulfate for binding to bFGF (Figs 1 and 2) ; this indicates that the binding site for PG-M-CSF and for heparan sulfateheparin are located close together on bFGF. Chondroitin sulfate B (also known as dermatan sulfate) inhibited PG-M-CSF binding to immobilized bFGF, although it was a less effective inhibitor than heparan sulfate ( Fig  1B) . This might reflect chondroitin sulfate B having a lesser binding capacity for bFGF than heparin."
Heparinlike molecules in the ECM have been proposed to act as a storage site for bFGF in Furthermore, recent studies have indicated that bFGF binding to heparin For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From is required for the binding of bFGF to its cell-surface receptor and for the bFGF-mediated stimulation of fibroblast growth and myoblast differentiation."^'" It has been proposed that the binding of bFGF to heparin may concentrate the ligand at the cell surface and present it in a conformation necessary for optimal interaction with high-affinity receptors, or this binding may affect the oligomerization of the ligand and favor the dimerization of bFGF receptors.".*" In this study, we also showed that PG-M-CSF significantly reduced bFGF-induced stimulation of DNA synthesis in Balbk 3T3 cells (Fig 5) . It is reasonable to assume that PG-M-CSF inhibits the cellular response to bFGF by interfering with the binding of the ligand to its receptor, through competing with the binding of bFGF to heparinlike molecules. However, the exact mechanism whereby PG-M-CSF inhibits bFGF action remains to be determined. Theoretically, soluble heparin would compete for cell-associated binding sites for bFGF and reduce the mitogenic response of cells to the growth factor. In fact, we found that when a 3-hour incubation with bFGF was performed in the presence of heparin and the cells were then washed and subjected to a further incubation in medium without bFGF and heparin, the stimulation of DNA synthesis was significantly reduced (Fig 5A) . However, if cells were incubated with bFGF and heparin continuously, heparin had relatively less of an inhibitory effect on bFGF action (Fig 5B) , as reported previously.25 Heparin has been shown to bind specifically to the cell surfaces of many cell types2'; thus, the addition of heparin in soluble form to cells might result in the establishment of cell-associated heparin in long-term incubation, which might replace endogeneous heparinlike molecules.
When the effect of bFGF on M-CSF activity was examined in a murine myeloid M-NFS-60 cells, which grow rapidly in response to M-CSF," the addition of up to I p,g/mL of bFGF had no effect on the PG-M-CSF-induced stimulation of cell growth (S. Suzu et al, unpublished observations, September 1993 ). This result is in good accordance with previous studies"; fully active forms of M-CSF have been produced by using constructs that express as few as 150 amino terminal residues, and it has been shown that the carboxyl terminal region of M-CSF is not required for in vitro activity.
The relevance of PG-M-CSF binding to bFGF and its inhibitory effect on the mitogenic activity of bFGF in vivo is not known. Basic FGF has been shown to stimulate M-CSF production in murine C3H 10T1/2 fibroblastsz9 and murine TC-1 stromal cells.3" Thus, the ability of PG-M-CSF to inhibit bFGF activity suggests that PG-M-CSF serves as a negative-feedback regulator of bFGF activity. bFGF is a very potent mitogen for various cells of mesodermal and neurodermal origin in vitro, and this growth factor also induces angiogenesis in vivo.".32 Further, accumulating data have shown that many solid tumors produce bFGF and that the factor is responsible both for their autonomous growth and for the neovascularization induced by the tumor cells.'".'' The present study suggests that PG-M-CSF or PG-M-CSF-derived peptides, because of their inhibitory effect on bFCF action, are potent agents that exert antitumor growth and antitumor angiogenesis effects.
